Figure 6: MPs enhance tumour cell susceptibility to chemotherapy.
From: Delivery of chemotherapeutic drugs in tumour cell-derived microparticles
(a) MPs decreased the efflux of drugs in H22 cells. H22 tumour cells were incubated with H22 cell-derived MPs for 12 h, then treated with 1 μg ml−1 doxorubicin. After 6 h, the supernatant was replaced with the fresh medium for another 6 h culture. The drug efflux by tumour cells was evaluated by flow cytometry and presented as the decrease of MFI. Data were combined from four reproducible experiments. Bars correspond to mean±s.d. (b) MPs increased the sensitivity of H22 cells to drugs. H22 tumour cells were with or without the pretreatment of MPs and then incubated with different concentrations of MTX. After 6 h, the cells were washed and continued another 16 h culture. Apoptosis was determined by flow cytometry. Ten thousand events were collected for this analysis. Representative FACS profiles are shown on the left and the combined data from four reproducible experiments are shown on the right. Bars correspond to mean±s.d. *P<0.05, compared with control.
